Original Research ARTICLE
Modulation of T-bet and Eomes during Maturation of Peripheral Blood NK Cells Does Not Depend on Licensing/Educating KIR
- 1Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
- 2Transplantation Immunology Unit, National Reference Laboratory for Histocompatibility, Department of Genetics and Laboratory Medicine, University Hospital Geneva, Geneva, Switzerland
Peripheral natural killer (NK) cells upregulate T-bet and downregulate Eomes, the key transcription factors regulating NK cell maturation and function during the last maturation steps toward terminally differentiated effector cells. During this process, NK cells acquire killer immunoglobulin-like receptors (KIR) and effector functions, such as cytotoxicity and target cell-induced cytokine production. Inhibitory KIR are pivotal in the control of effector functions, but whether they also modulate T-bet/Eomes expression is unknown. We have measured T-bet/Eomes levels, KIR expression, and effector functions of maturing CD94negCD56dimNK cells using CD57 as surface marker for maturation. Our cohort consisted of 23 healthy blood donors (HBD) homozygous for the KIR A haplotype that contains only inhibitory KIR2DL1 (ligand HLA-C2), KIR2DL3 (ligand HLA-C1), and KIR3DL1 (ligand HLA-Bw4). We confirm that during maturation of NK cells, the number of KIR increases, levels of T-bet/Eomes are modulated, and that cells acquire effector functions, such as cytotoxicity (CD107) and target cell-induced cytokine production (TNF-α). Because maturation was associated with the increase of the number of KIR as well as with the modulation of T-bet/Eomes, the number of KIR correlated with the extent of T-bet/Eomes modulation. However, whether the KIR were triggered by their cognate HLA ligands or not had no impact on T-bet and Eomes expression, indicating that modulation of T-box transcription factors during NK cell maturation does not depend on signals conveyed by KIR. We discuss the relevance of this finding in the context of models of NK cell maturation while cautioning that results obtained in a perhaps quite heterogeneous cohort of HBD are not necessarily conclusive.
Natural killer (NK) cells are involved in the early response to pathogens as well as in the recognition of autologous cells under stress induced by infection or transformation (1). Maturation toward an end-stage cytotoxic effector cell is associated with the loss of CD94 and acquisition of killer immunoglobulin-like receptors (KIR), of markers such as CD57 and of fine-tuning of effector functions (2–5). Activation of NK cells depends on an aggregate of signals conveyed by various activating and/or inhibitory receptors. Responsiveness to self is reduced through the triggering of inhibitory KIR by their ligands that consist of allelic variants of MHC molecules that are clustered in three groups, HLA class I ligands (HLA-C1, HLA-C2, and HLA-Bw4). NK cells without inhibitory KIR for self may remain harmless either because acquisition of the most potent effector functions (arming) requires interaction of inhibitory KIR with self-ligands or because NK cells stimulated by activating receptors in the absence of interaction of inhibitory KIR with self reduce responsiveness. These latter two processes are referred to as “licensing” (6, 7) and “education” (8, 9). The ensuing level of responsiveness may still be adapted to their immunological environment in mature NK cells, but the molecular mechanisms have not been established yet [recently reviewed in Ref. (10)].
T-bet and Eomesodermin (Eomes), two T-box transcription factors, are master regulators of T cell effector functions, including cytotoxicity and interferon-gamma (IFN-γ) production (11, 12). Furthermore, recent reports have shown that these two transcription factors also regulate maturation and function of NK cells. Murine (13) and human (14, 15) NK cells express T-bet and Eomes constitutively, and mice lacking both T-bet and Eomes are completely deprived of NK cells (16). Moreover, the two T-box transcription factors are modulated during NK cell differentiation (14, 17, 18) and are necessary for maintenance and differentiation of peripheral NK cells, while their deletion in mature NK cells results in reversion to an immature phenotype (16).
Mature NK cells express more licensing/educating KIR, are more cytotoxic, and proliferate less (2, 4). Whether they produce more cytokines after stimulation with target cells remains under debate (4, 19). Furthermore, they have downregulated Eomes and upregulated T-bet (14, 20). The concurrence of these processes has made it difficult to determine whether licensing is associated with, or the cause of the modulation of effector functions as well as T-bet/Eomes expression. It has been difficult to establish that signals conveyed by inhibitory KIR encountering their ligands induce maturation. Indeed, one could also argue that the increase in effector functions found to be correlated with the expression of such KIR simply reflects a licensing-independent concomitant NK cell maturation (4).
T-bet and Eomes induce NK cell maturation by suppressing CD27 and c-kit and upregulating S1P5 and KLRG1 [recently reviewed in Ref. (21)]. Hence, if signals through licensing receptors induce maturation, one would expect that the same signals would modulate the levels of T-bet and Eomes first. In this report, we measured T-bet and Eomes levels in maturing NK cells in 23 healthy blood donors (HBD) that were homozygous for the KIR A haplotype, which comprises only inhibitory KIR for their respective HLA-C or HLA-Bw4 ligands. We found that T-bet and Eomes were modulated in parallel with the increase of KIR, but whether the ligand for the KIR was present or not had no impact. This finding strengthens the model of a recently put forward (4), licensing-independent concomitant NK cell maturation.
Materials and Methods
DNA Extraction and KIR Genotyping
Killer immunoglobulin-like receptors genotyping was performed on DNA extracted from 400 μl of blood using QIAmp Blood Mini kit (Qiagen) with the KIR Genotyping SSP kit (Invitrogen) according to manufacturer’s instructions. The AA haplotype was defined as KIR2DL5Aneg/KIR2DL5Bneg/KIR2DS1neg/KIR2DS2neg/KIR2DS3neg/KIR2DS5neg/KIR2DS1neg.
HLA-A, B, C typing was performed by PCR-SSO hybridization on microbeads arrays (Luminex technology), using the LabType high definition reagents (One Lambda, Canoga Park, CA, USA). When required for the assignment of the HLA-C1 and -C2 groups, typing ambiguities were resolved by PCR-SSP using Olerup SSP kits (Milan Analytika AG, La Roche, Switzerland).
FACS Analysis, Effector Function Tests
Peripheral blood mononuclear cells (PBMCs) from AA haplotype homozygous donors blood from the Geneva University Hospitals blood transfusion center who gave informed consent by signing a standard form approved by the hospital’s ethical commission were isolated from anticoagulated blood by Ficoll density gradient centrifugation. We performed FACS analysis with monoclonal antibodies specific for the following antigens: CD158a (FITC, HP-MA4, Biolegend), CD57 (PECF594, clone NK1, BD Biosciences), CD94 (PerCPCy5.5, clone HP-3D9, BD Biosciences), CD158b (PEVio770, clone DX27, Miltenyi), CD158e (Alexa700, clone DX9, Biolegend), CD3 (APCH7, clone SK7, BD Biosciences), CD56 (BV421, cloneHCD56, Biolegend), CD107a (BV605, clone H4A3, Biolegend), TNF-α (BV605, clone MAb11, Biolegend), IFN-γ (BV605, clone 4S.B3, Biolegend), Eomes (eFluor 660, clone WD1928, e-Bioscience), and T-bet (PE, clone 4B10, e-Bioscience).
Effector functions were measured by stimulating PBMC at 37°C with K562 (cytotoxicity, TNF-α production) or with IL2/12/18 (IFN-γ production) as described before (20). Anti-CD107a was added at the start of the culture set up to measure degranulation. After 1 h, GolgiStop and GolgiPlug (BD Biosciences) were added, and cells were cultured for a further 3 h (CD107 and TNF-α) or 5 h (IFN-γ detection).
Intracellular staining for TNF-α, IFN-γ, Eomes, and T-bet was performed overnight at 4°C on permeabilized cells with FoxP3/transcription factor staining buffer set (e-Bioscience). CD3negCD56neg lymphocytes in the same blood sample were considered as Eomes and T-bet negative cells.
Data acquired on a Gallios 3 cell analyzer (BD Biosciences) were analyzed with FlowJo software (Tree Star Inc.) with the gates depicted in Figure 1. The first two gates (Figures 1A,B) were used to demarcate NK cells as CD3negCD56pos cells with the FSC/SSC of lymphocytes. CD56bright and CD56dim NK cells were discriminated on basis of the level of CD56-expression (Figure 1C). Maturation state (CD57), effector functions, and T-bet/Eomes levels of CD94neg (Figure 1D), CD56dim NK cells were measured in the respective eight subsets defined by the expression KIR2DL1, KIR2DL3, and KIR3DL1 (Figures 1E,F). Levels of T-bet and Eomes are expressed as mean fluorescence intensity ratio (MFIR), representing the mean fluorescence of T-bet/Eomes divided by the fluorescence of T-bet/Eomes negative CD3negCD56neg cells in the same sample. The percentage of CD107pos cells is expressed as %CD107pos NK cell after stimulation with K562 – % CD107pos unstimulated NK cell.
Figure 1. Gating strategies for KIR subset analysis. (A) Lymphocyte gates on FSC and SSC. (B) NK cell defined as CD56posCD3neg lymphocytes. (C) CD56bright and CD56dim NK cells according to the level of CD56-expression and gate on CD56dimCD94neg NK cells used for further analysis. (D–F) CD56dimCD94neg cells according to KIR expression (eight subsets). Q1: KIR2DL1negKIR2DL3negKIR3DL1pos, Q2: KIR2DL1posKIR2DL3negKIR3DL1pos, Q3: KIR2DL1negKIR2DL3negKIR3DL1neg, Q4: KIR2DL1posKIR2DL3negKIR3DL1neg, Q5: KIR2DL1negKIR2DL3posKIR3DL1pos, Q6: KIR2DL1posKIR2DL3posKIR3DL1pos, Q7: KIR2DL1negKIR2DL3posKIR3DL1neg, Q8: KIR2DL1posKIR2DL3posKIR3DL1neg. Examples of fluorescence intensity of CD57 (G), Eomes (H) and T-bet (I) according to the number of KIR expressed with their respective negative controls.
Non-parametric Wilcoxon matched-pairs signed rank test or Mann–Whitney test were used to compare groups, p values >0.05 were considered as not statistically significant.
We have studied maturing NK cells in 23 KIR A haplotype homozygous HBD that comprise only the inhibitory variant of KIR2DL1, KIR2DL3, and KIR3DL1. This allowed us to measure the effect of the presence or absence of HLA ligands on inhibitory KIR using monoclonal antibodies that also recognize their activatory variants. Table 1 shows the KIR and HLA class I molecules expressed by the 23 HBD tested. As expected for KIR A haplotype homozygous individuals, NK cell subpopulations expressing KIR2DL1 and KIR2DL3 were present in all HBD. Two of 23 HBD lacked NK cells expressing KIR3DL1, which is owed to the fact that some KIR3DL1 allelic variants are not expressed at the protein level (22). The last three columns of the table show in which HBD the respective KIR encounter their cognate ligands [KIR2DL1↔C2, KIR2DL3↔C1, and KIR3DL1↔Bw4 epitope on HLA-B antigens as well as the HLA-A antigens (23, 24) marked in bold]. Hence, KIR2DL1 encountered its cognate HLA ligand in 10/23 and KIR2DL3 in 22/23 HBD, while KIR3DL1 was able to license NK cells in 15/23 HBD.
Expression of Eomes/T-bet/CD57 in Relation to the Number of KIR
Several reports have shown that NK cells upregulate CD57 and increase the number of KIR expressed during maturation. In parallel, CD56dim NK cells downregulate Eomes and upregulate T-bet. Using the gating strategy shown in Figure 1, we measured the levels of CD57, Eomes, and T-bet in CD56bright NK cells and in the eight NK cell subpopulations of CD56dimCD94neg NK cells expressing different combinations of KIR2DL1, KIR2DL3, and KIR3DL1. Figure 2 shows the results of our panel of 23 HBD and confirms (Figures 2A,B) that indeed CD57 levels on CD94negKIRposCD56dim NK cells are significantly higher than on CD94negKIRnegCD56dim NK cells, and that CD57 levels increase further with the number of KIR expressed (for comparison, CD57, Eomes and T-bet levels on CD56bright NK cells are shown). This was true when all KIR (Figure 2A) or only licensing KIR (Figure 2B) were considered. Furthermore, levels of Eomes that are significantly lower in CD56dim NK cells than in CD56bright NK cells (Figures 2C,D) are further downregulated with the acquisition of KIR. As expected, T-bet levels were the opposite of Eomes levels. CD56dim NK cells expressed more T-bet than their CD56bright counterparts, and these levels increased with the number of KIR expressed (Figures 2E,F). Again, whether all KIR were licensing (Figures 2D,F) or not (Figures 2C,E) did not seem to have a considerable impact.
Figure 2. CD57 and T-bet are upregulated, while Eomes is downregulated during NK cell maturation and KIR acquisition. Expression levels of CD57 (A,B), eomes (C,D), and T-bet (E,F) in CD56bright or in CD56dim CD94neg cells according to the number of KIR (A,C,E) or licensing KIR (B,D,F) expressed. Medians are shown, and Wilcoxon matched-pairs signed rank test was used for statistical analysis, p values are indicated. As mentioned in the text, CD94pos NK cells have been excluded from analysis because, although the results are very similar (not shown), the inclusion of CD94pos NK cells would render the interpretation of the results more difficult.
Eomes/T-bet/CD57 Expression and Effector Function of Licensed and Unlicensed NK Cells
To investigate the effect of licensing on Eomes/T-bet levels more precisely, we gated on CD56dim NK cells expressing a single KIR and tested the impact of the presence or absence of its HLA ligand. Furthermore, we gated on CD94neg NK cells to disregard the weaker inhibitory signals through CD94/NKG2A (25), of which the contribution to licensing is unclear. Figures 3A,B show that the expression of Eomes/T-bet in licensed NK cells was identical to the level in unlicensed NK cells. This was true for single KIR2DL1pos NK cells in the presence (HBD 1–3, 8, 9, 11, 12, 14, 16, 18) or in the absence (HBD 4–6, 7, 10, 13, 15, 17, 19–23) of its ligand HLA-C2 (Figure 3C) as well as for single KIR3DL1pos NK cells in the presence (HBD 1, 3, 4, 6–11, 14, 15, 18–21) or in the absence (HBD 2, 5, 12, 13, 16, 17, 22, 23) of its ligand HLA-Bw4 (Figure 3D). We were not able to compare the effect of the ligand HLA-C1 on single KIR2DL3pos NK cells because our panel comprised only one HLA-C1 negative HBD (HBD 11), but the fact that the Eomes/T-bet levels in licensed single KIR2DL3pos NK cells (HBD 1–10, 12–23) was identical to the levels in (un)licensed single KIR2DL1pos or KIR3DL1pos NK cells did suggest that the effect of licensing in single KIR2DL3pos NK cells may also be negligible.
Figure 3. Licensing has no effect on eomes, T-bet, and CD57 expression. Eomes (A), T-bet (B), and CD57 (E) MFIR are shown in CD56dimCD94neg cells expressing a single licensed (L) or unlicensed (U) KIR. Eomes (C) and T-bet (D) MFIR are represented for each KIR separately. Medians are shown, and Mann–Whitney test was used for statistical analysis.
Licensed and unlicensed NK cells expressed similar levels of CD57 (Figure 3E), but effector functions that were higher in cells expressing more KIR (data not shown) were to some extent affected by licensing. Licensed NK cells produced significantly more TNF-α than unlicensed NK cells (Figure 4A), and the most cytotoxic NK cells (Figure 4B) were licensed. Hence, we found that the effect of licensing on maturation and effector functions of human NK cells may be of secondary importance only, which in our opinion accords well with the variegated results on the effect of licensing on different effector functions of human NK cells reported by others (2, 4, 19).
Figure 4. Impact of licensing on TNF-α production and cytoxicity in CD56dimCD94neg cells. TNF-αpos (A) and CD107pos (B) cells in CD56dimCD94neg cells expressing a single licensed (L) or unlicensed (U) KIR after culture for 3 h in presence of K562 target cells. Medians are shown, and Mann–Whitney test was used for statistical analysis, p values are indicated when significant.
The expression of the master regulators of NK cell differentiation T-bet and Eomes is modulated during the maturation toward end-stage cytotoxic NK cells. Cytokine-producing CD56bright NK cells express higher levels of Eomes and lower levels of T-bet than cytotoxic CD56dim NK cells, and the T-bet/Eomes ratio increases further during the last maturation steps toward terminally differentiated CD56dimCD57pos NK cells (14, 15, 20). During maturation, the number of KIR increases, markers such as CD94 and CD62L are downregulated, CD57 is upregulated, and effector functions change (2–5).
There are indications that licensing favors maturation, but the extent thereof remains under debate (2, 4, 19). It is conceivable that licensing modulates T-bet and Eomes and that the ensuing upregulation of T-bet is at the origin of the increased cytotoxicity that is characteristic of mature NK cells. However, it may also be that licensing, upregulation of T-bet, and the increase of cytotoxicity are maturation-associated, parallel processes.
To answer this question, we measured T-bet and Eomes levels in maturing NK cells that were licensed or not. We found no differences in T-bet/Eomes levels in licensed or unlicensed NK cells. Although this would indicate that licensing and modulation of T-bet and Eomes are independent processes, we remain somewhat reluctant to draw such a firm conclusion based on the analysis of a panel of perhaps quite heterogeneous HBD. In humans, it might not be that easy to discriminate between cells that have matured in response to signals through licensing KIR or in response to cytokines (6, 7, 26, 27) produced during an inflammatory immune response. Indeed, mouse models have been somewhat more consistent regarding the effect of licensing on effector functions (6, 28, 29) than human studies (2, 4, 8, 19, 30). Likewise, our results regarding the acquisition of effector functions or of a more mature phenotype of CD56dimCD94neg single KIRpos NK cells in the presence or absence of their cognate HLA ligand were not very conclusive. Licensed NK cells produced more TNF-α, seemed to be somewhat more cytotoxic but did not express more CD57 than unlicensed cells. We also measured differences in IFN-γ production, the cytokine that is commonly tested in functional studies of NK cells. We found no differences, but again, we consider these results with caution because in our hands only few NK cells ex vivo produce IFN-γ when stimulated with target cells without being cultured in the presence of IL2/IL-12/IL-18 (20). Licensed and unlicensed CD56dim NK cells produced similar quantities of IFN-γ after stimulation with cytokines (data not shown), but this result is not more than had to be expected because the culture with cytokines would simply annul potential differences between licensed and unlicensed NK cells.
In conclusion, we found no impact of licensing on the expression of T-bet and Eomes.
Because T-bet and Eomes are the master regulators of NK cell maturation, these results are hard to reconcile with the model in which licensing induces maturation directly. However, because we also found that the effect of licensing was not easily substantiated for classical maturation-associated attributes, such as cytokine production, cytotoxicity, and expression of CD57, we believe that this finding should be interpreted with caution. In fact, human NK cells may not be ideal to study the effect of licensing on maturation because the circumstances in vivo that may bypass the need for licensing are hard to define.
AP, FS, and ER designed the study; AP and CB performed the experiments; SW organized the cohort of HBD; J-MT helped with HLA and KIR-typing; AP and ER wrote the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
ER is supported by grants from the Swiss National Science Foundation and the Swiss Cancer Research. FS is supported by grants from the Geneva University Hospitals’ Clinical Research Center and the Dubois-Ferrière-Dinu-Lipatti Foundation.
2. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood (2010) 116:1299–307. doi:10.1182/blood-2009-11-253286
3. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK cell subset. Blood (2010) 116(19):3865–74. doi:10.1182/blood-2010-04-282301
4. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK cell differentiation uncoupled from NK cell education. Blood (2010) 116:3853–64. doi:10.1182/blood-2010-04-281675
5. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets. Blood (2010) 115(2):274–81. doi:10.1182/blood-2009-04-215491
6. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 436(7051):709–13. doi:10.1038/nature03847
7. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann T, et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood (2007) 110:578–86. doi:10.1182/blood-2006-07-036228
11. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science (2003) 302(5647):1041–3. doi:10.1126/science.1090148
12. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med (2009) 206:51–9. doi:10.1084/jem.20081242
13. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 6:1236–44. doi:10.1038/ni1268
14. Luetke-Eversloh M, Cicek BB, Siracusa F, Thom JT, Hamann A, Frischbutter S, et al. NK cells gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol (2014) 44(7):2074–84. doi:10.1002/eji.201344072
16. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity (2012) 36:55–67. doi:10.1016/j.immuni.2011.11.016
17. Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med (2014) 211(3):563–77. doi:10.1084/jem.20131560
18. Gotthardt D, Prchal-Murphy M, Seillet C, Glasner A, Mandelboim O, Carotta S, et al. NK cell development in bone marrow and liver: site matters. Genes Immun (2014) 15:584–7. doi:10.1038/gene.2014.55
19. Lin L, Ma C, Wei B, Aziz N, Rajalingam R, Yusung S, et al. Human NK cells licensed by killer Ig receptor genes have an altered cytokine program that modifies CD4+ T cell function. J Immunol (2014) 193(2):940–9. doi:10.4049/jimmunol.1400093
20. Simonetta F, Pradier A, Bosshard C, Masouridi-Levrat S, Chalandon Y, Roosnek ENK. Cell functional impairment after allogeneic hematopoietic stem cell transplantation is associated with reduced levels of T-bet and eomesodermin. J Immunol (2015) 195:4712–20. doi:10.4049/jimmunol.1501522
22. Thomas R, Yamada E, Alter G, Martin MP, Bashirova AA, Norman PJ, et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol (2008) 180:6743–50. doi:10.4049/jimmunol.180.10.6743
24. Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS. The reactivity of Bw4-positive HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplants. Blood (2008) 112(2):435–43. doi:10.1182/blood-2008-01-132902
25. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol (2007) 179:5977–89. doi:10.4049/jimmunol.179.9.5977
26. Grau R, Lang KS, Wernet D, Lang P, Niethammer D, Pusch CM, et al. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals. Exp Mol Pathol (2004) 76(2):90–8. doi:10.1016/j.yexmp.2003.12.002
28. Johansson S, Johansson M, Rosmaraki E, Vahlne G, Mehr R, Salmon-Divon M, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med (2005) 201(7):1145–55. doi:10.1084/jem.20050167
29. Brodin P, Lakshmikanth T, Johansson S, Karre K, Hoglund P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood (2009) 113(11):2434–41. doi:10.1182/blood-2008-05-156836
Keywords: NK cell, maturation, KIR, licensing, T-Bet, Eomes
Citation: Pradier A, Simonetta F, Waldvogel S, Bosshard C, Tiercy J-M and Roosnek E (2016) Modulation of T-bet and Eomes during Maturation of Peripheral Blood NK Cells Does Not Depend on Licensing/Educating KIR. Front. Immunol. 7:299. doi: 10.3389/fimmu.2016.00299
Received: 29 April 2016; Accepted: 25 July 2016;
Published: 24 August 2016
Edited by:Jordan Orange, Baylor College of Medicine, USA
Reviewed by:Jeroen Van Bergen, Leiden University, Netherlands
Nicholas D. Huntington, The Walter and Eliza Hall Institute of Medical Research, Australia
Copyright: © 2016 Pradier, Simonetta, Waldvogel, Bosshard, Tiercy and Roosnek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eddy Roosnek, email@example.com